https://www.yiliao.com/index.php?action=history&feed=atom&title=%E9%AB%98%E7%BA%A7%E5%88%AB%E6%B5%86%E6%B6%B2%E6%80%A7%E7%99%8C
高级别浆液性癌 - 版本历史
2026-04-20T05:50:16Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E9%AB%98%E7%BA%A7%E5%88%AB%E6%B5%86%E6%B6%B2%E6%80%A7%E7%99%8C&diff=313474&oldid=prev
223.160.138.166：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-07T05:26:38Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[高级别浆液性癌]]([[High-Grade Serous Carcinoma, HGSC]])</strong>是卵巢癌、输卵管癌及原发性腹膜癌中最常见且最具侵袭性的病理亚型，约占所有上皮性卵巢癌的70%-80%。在2026年的分子病理学共识中，[[HGSC]]被确认为主要起源于输卵管远端的<strong>[[输卵管浆液性原位癌]]([[STIC]])</strong>。其核心遗传特征为近100%的<strong>[[TP53]]</strong>基因突变以及约50%的<strong>[[同源重组修复缺陷]]([[HRD]])</strong>。由于其极易发生腹膜播散且早期诊断困难，2026年的治疗重点已转向基于<strong>[[BRCA1/2]]</strong>状态的<strong>[[PARP抑制剂]]</strong>一线维持治疗及针对铂类耐药阶段的<strong>[[FR&alpha;-ADC]]</strong>靶向干预。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">高级别浆液性癌</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">High-Grade Serous Ca.·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 15px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Histology: Slit-like spaces and significant nuclear pleomorphism</div><br />
</div><br />
<br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心驱动：[[TP53]]/[[BRCA1]]/[[BRCA2]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">7157([[TP53]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]编号</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">11998</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P04637</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">ICD-11编码</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2C70.0</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">起源学说</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">输卵管起源([[STIC]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">关键指标</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[HRD]]状态•[[FR&alpha;]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026热点</th><br />
<td style="padding: 12px; color: #b91c1c;">ADC联合免疫序贯</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：基因组灾难与修复缺陷</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[HGSC]]的生物学特征是极端的基因组不稳定性。2026年的分子解析将其发病机制归纳为以下级联：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>TP53 早期事件：</strong> 几乎所有的[[HGSC]]在癌前病变（[[STIC]]）阶段即已携带<strong>[[TP53]]</strong>突变。这种“**[[p53签名]]**”导致细胞失去周期检查点控制，引发大规模的拷贝数变异（[[SCNAs]]）。</li><br />
<li style="margin-bottom: 12px;"><strong>同源重组修复缺失([[HRD]])：</strong> 约50%的患者存在[[HR]]路径缺陷。除<strong>[[BRCA1/2]]</strong>胚系或体细胞突变外，还包括[[RAD51C/D]]、[[PALB2]]突变或[[BRCA1]]启动子甲基化。这造成了DNA双链断裂修复障碍，为<strong>[[合成致死]]</strong>策略提供了天然靶点。</li><br />
<li style="margin-bottom: 12px;"><strong>CCNE1 扩增路径：</strong> 在约20%的非[[HRD]]患者中，观察到<strong>[[CCNE1]]</strong>（细胞周期蛋白E1）的显著扩增。这类患者通常表现为对铂类药物原发耐药，是2026年针对[[CDK]]抑制剂研究的重点人群。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026全球 HGSC 循证治疗决策矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">临床场景</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">2026 标准方案([[SOC]])</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键生存获益依据</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">一线维持(BRCA+)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[奥拉帕利]]单药维持[[2年]]。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[SOLO-1]]：中位[[PFS]]突破56个月。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">一线维持(HRD+)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[奥拉帕利]]+[[贝伐珠单抗]]。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[PAOLA-1]]：针对HRD+人群显着提升[[OS]]。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">铂类耐药(FR&alpha;+)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[索米妥昔单抗]]</strong>(FR&alpha;-ADC)。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[MIRASOL]]：相比化疗显着延长总生存期。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">复发监测</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[ctDNA]]+[[CA-125]]双模监测。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">2026共识：ctDNA可提前[[4-6个月]]预警复发。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：从手术彻底性到全程靶向</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[HGSC]]的管理在2026年强调“外科手术与分子维持的无缝衔接”：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>R0 根治术的绝对优先：</strong> 2026规范重申：首次细胞减灭术（[[PDS]]）实现<strong>[[无肉眼残留病灶]]([[R0]])</strong>是决定长期生存的第一因素。针对不可直接根治者，推荐[[新辅助化疗]]后的间歇期手术（[[IDS]]）。</li><br />
<li style="margin-bottom: 12px;"><strong>维持治疗的精细分层：</strong> 2026版[[NCCN]]明确：所有晚期[[HGSC]]患者必须在术后进行<strong>[[BRCA]]</strong>和<strong>[[HRD]]</strong>（同源重组缺陷评分）检测。根据检测值决定[[PARP抑制剂]]单用或联合[[VEGF抑制剂]]。</li><br />
<li style="margin-bottom: 12px;"><strong>耐药后的ADC切换：</strong> 针对铂类耐药型[[HGSC]]，2026年临床路径首选检测<strong>[[叶酸受体&alpha;]]([[FR&alpha;]])</strong>表达。阳性者应立即进入[[ADC]]治疗模式，以避免无效化疗带来的毒性积聚。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[STIC]]：</strong> 输卵管浆液性原位癌，[[HGSC]]公认的早期起源形式。</li><br />
<li style="margin-bottom: 8px;"><strong>[[HRD]]：</strong> 同源重组修复缺陷，是[[HGSC]]最重要的精准治疗分型指标。</li><br />
<li style="margin-bottom: 8px;"><strong>[[合成致死]]：</strong> PARP抑制剂治疗[[BRCA]]突变肿瘤的核心药理学逻辑。</li><br />
<li style="margin-bottom: 8px;"><strong>[[索米妥昔单抗]]：</strong> 商品名[[Elahere]]，重塑铂类耐药[[HGSC]]治疗格局的[[ADC]]药物。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Bowtell DD, et al. (2015/2026Update).</strong> <em>Rethinking ovarian cancer II: reducing mortality from high-grade serous carcinoma.</em> <strong>[[Nature Reviews Cancer]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该项经典综述的2026年修订版系统阐述了从预防性切除到分子精准干预的全链条降死率方案。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>[[ESMO]] Clinical Practice Guidelines. (2025/2026Revision).</strong> <em>Newly Diagnosed and Relapsed Ovarian Cancer: Focus on HGSC.</em> [Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：2026年指南修正强调了HRD评分在初诊患者中作为一类推荐的绝对地位。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
高级别浆液性癌 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[TP53]]•[[BRCA1/2]]•[[PARP1]]•[[FR&alpha;]]•[[VEGF]]•[[CCNE1]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[奥拉帕利]]•[[尼拉帕利]]•[[索米妥昔单抗]]•[[贝伐珠单抗]]•[[顺铂]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[SinoCellGene协作]]•[[MSKCC]]•[[Mayo Clinic]]•[[CSCO]]•[[NCCN]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究领域</td><br />
<td style="padding: 10px 15px; color: #334155;">[[基因组不稳定性]]•[[同源重组]]•[[液体活检]]•[[合成致死]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.166